tiprankstipranks
Trending News
More News >

Neuren Pharmaceuticals Issues New Equity Securities Under Employee Scheme

Story Highlights
Neuren Pharmaceuticals Issues New Equity Securities Under Employee Scheme

Don’t Miss TipRanks’ Half-Year Sale

An update from Neuren Pharmaceuticals Limited ( (AU:NEU) ) is now available.

Neuren Pharmaceuticals Limited announced the issuance of 210,000 unquoted equity securities under an employee share scheme. This move is part of the company’s strategy to incentivize and retain talent, potentially strengthening its operational capabilities and aligning employee interests with company growth.

The most recent analyst rating on (AU:NEU) stock is a Buy with a A$31.40 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.

More about Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurodevelopmental disorders. The company is known for its work on treatments for conditions such as Rett syndrome and Fragile X syndrome, aiming to address unmet medical needs in these areas.

Average Trading Volume: 617,468

Technical Sentiment Signal: Buy

Current Market Cap: A$1.77B

See more data about NEU stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1